5-Amino-1MQ vs PT-141
Head-to-head comparison of 5-Amino-1MQ (5-Amino-1-methylquinolinium) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | 5-Amino-1MQ | PT-141 |
|---|---|---|
| Category | Weight Management | Performance |
| Full Name | 5-Amino-1-methylquinolinium | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 178.23 g/mol | 1,025.2 Da |
| Half-Life | ~6 hours | ~2.7 hours |
| Amino Acids | Small molecule | 7 |
| Typical Dose | — | 1.75 mg |
| Route | — | SC |
| Purity | >98% | — |
| Studies Count | 28 | 178 |
| Research Status | Active Research | FDA Approved |
5-Amino-1MQ Benefits
- ✓Reduces body fat without appetite changes, lowers cholesterol, increases NAD+ levels, improves metabolic efficiency, supports cellular energy production
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
5-Amino-1MQ Dosing
Research doses: 50-150 mg orally daily. Often cycled 8-12 weeks on, 4 weeks off. Best taken in the morning.
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
5-Amino-1MQ Side Effects
- ⚠Generally well-tolerated in preclinical models. Potential mild GI discomfort and headache. Long-term human safety data is limited.
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
5-Amino-1MQ
Studies in diet-induced obese mice showed significant reductions in body weight, white adipose tissue mass, and cholesterol levels without changes in food intake. Works by inhibiting NNMT enzyme to increase NAD+ and activate sirtuins.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.